The INSPIRE (Investigating New Standards for Prophylaxis In Reduction of Exacerbations) trial demonstrated that while the two study medications; Seretide™ 50/500µgDiskus™ (salmeterol/fluticasone propionate) and tiotropium bromide 18µg Handihaler® had a comparable effect on exacerbation rates, those who received Seretide experienced substantial health status improvements and better survival periods than those who received tiotropium. [click link for full article]
(more...)